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Abstract: Exposure to high levels of glucose and iron are co-related to reactive oxygen species (ROS) 
generation and dysregulation of insulin synthesis and secretion, although the precise mechanisms are 
not well clarified. The focus of this study was to examine the consequences of exposure to high iron 
levels on MIN6 β-cells. MIN6 pseudoislets were exposed to 20 µM (control) or 100 µM (high) iron at 
predefined glucose levels (5.5 mM and 11 mM) at various time points (3, 24, 48, and 72 h). Total iron 
content was estimated by a colourimetric FerroZine™ assay in presence or absence of transferrin­
bound iron. Cell viability was assessed by a resazurin dye-based assay, and ROS-mediated cellular 
oxidative stress was assessed by estimating malondialdehyde levels. β-cell iron absorption was de­
termined by a ferritin immunoassay. Cellular insulin release and content was measured by an insulin 
immunoassay. Expression of SNAP-25, a key protein in the core SNARE complex that modulates 
vesicle exocytosis, was measured by immunoblotting. Our results demonstrate that exposure to high 
iron levels resulted in a 15-fold (48 h) and 4-fold (72 h) increase in cellular iron accumulation. These 
observations were consistent with data from oxidative stress analysis which demonstrated 2.7-fold 
higher levels of lipid peroxidation. Furthermore, exposure to supraphysiological (11 mM) levels 
of glucose and high iron (100 µM) at 72 h exerted the most detrimental effect on the MIN6 β-cell 
viability. The effect of high iron exposure on total cellular iron content was identical in the presence or 
absence of transferrin. High iron exposure (100 µM) resulted in a decrease of MIN6 insulin secretion 
(64% reduction) as well as cellular insulin content (10% reduction). Finally, a significant reduction 
in MIN6 β-cell SNAP-25 protein expression was evident at 48 h upon exposure to 100 µM iron. 
Our data suggest that exposure to high iron and glucose concentrations results in cellular oxidative 
damage and may initiate insulin secretory dysfunction in pancreatic β-cells by modulation of the 
exocytotic machinery. 
Keywords: excess iron; oxidative stress; impaired insulin secretion; type 2 diabetes mellitus; β-cell 
1. Introduction 
Type 2 diabetes mellitus (T2DM), also known as insulin-dependent diabetes mellitus 
(IDDM), is a global health problem with a rapidly increasing incidence. As per the Interna­
tional Diabetes Foundation (IDF), there were more than 387 million people affected in 2014, 
and with numbers increasing every year this is projected to reach 592 million by 2035 [1]. 
T2DM represents a serious public health concern that is prevalent in both developed and 
developing countries [2]. 
Insulin is a key homeostatic regulator of blood glucose. Defects in both insulin secre­
tion and insulin action contribute to the development of T2DM [3]. Synaptosomal associ-
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ated protein 25 (SNAP-25) is one of core components of SNARE (soluble N-ethylmaleimide­
sensitive factor attachment protein receptor) proteins and contains amino acid and carboxy 
terminals that bind to different proteins [4]. SNAP-25 binds to syntaxin 1 and VAMP2 
and together the three SNARE proteins generate a steady bundle of the four α-helices, 
with each protein containing one α-helix (from VAMP and syntaxin), and two α-helices 
from SNAP23/25 [4]. These proteins have a crucial role in regulating = vesicle/granule 
exocytosis of not only insulin, but also sharing numerous commonalities with neuronal 
synaptic vesicle exocytosis [4]. ancreatic β-cells have a crucial role to synthesise and secrete 
insulin at appropriate rates. However, these cells are susceptible to oxidative damage [5], 
as they have relatively lower expression of protective antioxidant enzymes, such as catalase 
and glutathione peroxidase compared to other organs [6]. At low concentrations, reactive 
oxygen species (ROS) provide beneficial effects in many metabolic processes [7]. Unfor­
tunately, these powerful agents can be important mediators of damage to cell structures, 
nucleic acids, lipids, and proteins, that is associated with biochemical and functional 
changes [8]. Lipid peroxidation is one biological process resulting from the attack by metal-
induced generation of ROS, producing malondialdehyde (MDA) and 4-hydroxy-2-nonenal 
(4-HNE) [9]. 
As a consequence of exposure to high concentrations of ROS, pancreatic β-cell can 
experience oxidative stress, resulting in cellular toxicity [10]. Recent studies have shown 
that iron overaccumulation in the β-cell leads to increased mitochondrial iron transport, 
which induces mitochondrial dysfunction [11]. Iron overload contributes to various com­
plex diseases, including diabetes mellitus [12] and neurodegenerative diseases such as 
Alzheimer’s disease and Parkinson’s disease [13]. 
Iron is the most important trace element and is found in many essential enzymes 
and proteins. This transition metal exists in two valency states, Fe2+ (ferrous iron) and 
Fe3+ (ferric iron) and has various essential functional roles in the body including a vital 
contribution to the redox reactions of oxidative phosphorylation by accepting and donating 
electrons [14]. Unfortunately, the same properties that make iron useful can also make it 
toxic to cells. Through the generation of free radicals, iron can damage essential biological 
components such as DNA, proteins, and lipids [15]. Thus, an organism must have control 
over iron uptake, and its location and transport within the body. When the amount 
of free ferrous iron is elevated, it is believed to lead to the generation of ROS through 
Fenton and Haber-Weiss chemistry [16]. The hydroxyl radical (•OH) that is produced via 
Fenton chemistry is the most reactive oxygen radical and can readily react with biological 
molecules in its immediate vicinity causing significant damage [17]. •OH is a major species 
that attacks cell membrane lipids, proteins, and DNA and causes tissue damage leading to 
insulin resistance and eventually β-cell failure [18]. 
As described above, ROS clearly possess the capacity to behave as a destructive agent, 
and the key element to prevent this toxicity is the induction of antioxidant defense systems. 
Unfortunately, chronic oxidative stress could lead to the progression of pancreatic β-cell 
dysfunction due to a lack of significant protective agents. It is therefore important to 
improve our understanding of the relationship between iron and ROS-mediated changes 
in β-cell function. 
Thus, this study aimed to assess cellular oxidative dysfunction mediated by ROS in 
pancreatic β-cells and its effects upon cell viability, insulin synthesis, and secretion. The 
effect of β-cell oxidative stress on expression of SNAP-25, a key protein involved in the 
insulin exocytosis machinery, was also examined. 
2. Materials and Methods 
2.1. Materials 
All chemicals were cell culture grade and purchased from Sigma-Aldrich (Poole, UK) 
and Thermo Fisher Scientific (Loughborough, UK) unless otherwise stated. Murine MIN6 
cells were a kind gift from Dr. Bo Liu (Department of Diabetes, King’s College London, 
London, UK) at passage 34 (originally from Prof. Jun-ichi Miyazaki, Osaka University, 
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Osaka, Japan). Thiobarbituric Acid Reactive Substances (TBARS) parameter kit (Cat No. 
KGE013) was from R&D Systems (Abington, UK). PrestoBlueTM cell viability reagent 
was purchased from Thermo Fisher Scientific (Loughborough, UK, catalogue no. A13261). 
Ferritin ELISA kit (product code S-22) was from ATI Atlas (Chichester, UK). Mouse insulin 
ELISA was supplied by Mercodia (Cat No. 10-1247-01—Mercodia, Diagenics, Milton 
Keynes, UK). 
2.2. MIN6 Cell Culture 
Murine MIN6 cells were prepared and obtained at passage 34–40 in complete Dul­
becco’s Modified Eagle Medium (DMEM)—GlutaMax®, pH 7.4 supplemented with 15% 
Foetal Bovine Serum (FBS), 1% antibiotic/antimycotic solution and 25 mM HEPES. The 
cells were incubated in an atmosphere of 95% air and 5% CO2 at constant humidity. Stock 
cultures were grown at 37 ◦C in 75 cm2 T-flasks, replacing the medium every two days. 
Cells were seeded in 12-well plates with density of 25 × 104 cells/cm2 for all experimental 
cultures. MIN6 cells reached confluence within day 3–5 post-seeding by which point the 
phenotype of small clusters of cells was formed (Supplementary Figure S1), indicating the 
cells were functional and capable of secreting insulin [19]. 
2.3. MIN6 Cell Exposure to Glucose and Iron 
The glucose and iron exposure experiment was carried out using serum-free MEM with 
5.5 mM glucose. Media were supplemented with 2 mM L-glutamine, 1% antibiotic/antimycotic, 
0.1% BSA, and 25 mM HEPES, pH 7.4. Cells were seeded at 25 × 104 cells/cm2. The cells 
were iron depleted with serum-free media treatment and incubated overnight prior to 
conducting the experiment at 37 ◦C with 5% CO2. MIN6 cells were preincubated for 1 h in 
Krebs–Ringer Bicarbonate (KRB) buffer (119 mM NaCl, 4.74 mM KCl, 2.54 mM CaCl·6H2O, 
1.19 mM KH2PO4, 1.19 mM MgSO4·7H2O, 25 mM NaHCO3, 10 mM HEPES, pH 7.4, and 
1% BSA) containing 1.1 mM glucose (basal) before the glucose and iron stimulation. 
MIN6 cells were washed with DPBS and placed in KRB buffer containing varying 
concentrations of glucose (5.5 mM (physiological) and 11 mM (supraphysiological), and 
iron [20 µM (control) and 100 µM (high)], or a combination of both glucose and iron, with 
an addition of tolbutamide (100 µM) (Table 1). Preincubation was carried out at 3, 24, 
48, and 72 h time intervals. Cells then were lysed with RIPA buffer with the addition of 
protease inhibitor cocktail (PIC) and then subsequently stored at −20 ◦C. 
Table 1. Iron and glucose treatment conditions. 
Name of Condition Treatment Glucose Concentrations (mM) 
Iron Concentrations 
(µM) 
Ctrl Basal Glu 1.1 0 
C1 Glu 5.5 0 
C2 Glu 11 0 
C3 Fe 0 20 
C4 Fe 0 100 
C5 Glu + Fe 5.5 20 
C6 Glu + Fe 5.5 100 
C7 Glu + Fe 11 20 
C8 Glu + Fe 11 100 
2.4. Intracellular Total Iron Quantification 
Intracellular total iron levels were quantified using an optimised FerroZine™-based 
iron assay according to method developed by Reimer et al. [20]. Iron detection reagent 
was added into each standard and sample tube containing 6.5 mM FerroZine™, 6.5 mM 
neocuproine, 2.5 M ammonium acetate, and 1 M ascorbic acid dissolved in water. The 
standard or sample mixtures with reagents underwent incubation for 30 min at room 
temperature. Following incubation, colour development was observed and 280 µL from 
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both standard and sample tubes was added in duplicate into wells of a 96-well plate before 
the absorbance was measured at 550 nm using a microplate reader. Intracellular iron 
concentration was determined by normalising against a total protein standard curve which 
was obtained using the BCA assay. 
2.5. Intracellular Ferritin Quantification 
Ferritin content of MIN6 cells was determined using a commercial ELISA kit according 
to the manufacturer’s instructions. This experiment was followed by measuring the total 
protein content of MIN6 cells using a Pierce™ BCA kit (Thermo Fisher Scientific, Lough­
borough, UK, Cat No. 23225). The kit-provided Bovine Serum Albumin (BSA) was used as 
a stock (2 mg/mL) to prepare standards by serial dilutions. Samples were loaded in dupli­
cate into a 96-well plate (25 µL). Absorbance was measured at 490 nm with background 
correction at 630 nm using a microplate reader. Ferritin concentration was standardised 
against the total protein concentration determined by the BCA assay. 
2.6. Lipid Peroxidation Assessment 
The samples from the static incubation experiments stored at −20 ◦C were assessed for 
lipid peroxidation using a TBARS assay. Manufacturer’s protocol was followed with minor 
variations. A stock solution of 167 µM was prepared with a combination of 100 µL TBARS 
Standard and 200 µL TBARS Acid Reagent, kept at RT for 30 min with gentle agitation at 
30 RPM. TBARS Acid and TBA Reagent were added on each designated sample and placed 
in a water bath at 80 ◦C for 1.5 h. The absorbance was measured at 532 nm and followed 
by subtracting the pre-reading from the final reading. 
2.7. Measurement of Cellular Cytotoxicity 
Cells were prepared as described above and treated with iron/glucose for 3, 24, 48, 
and 72 h. PrestoBlueTM cell viability reagent was performed following manufacturer’s 
protocol (1 h incubation) to measure cell cytotoxicity. Absorbance was measured at 560–590 
nm and absorbance measures were compared to control cells. 
2.8. Estimation of Insulin Secretion and Content 
To determine insulin secretory response and content, MIN6 cells were incubated in 
the presence of KRB buffer and tolbutamide after which the media were collected. The 
supernatant was used to measure the secretion of insulin whereas the remaining cell pellets 
were used to analyse insulin content. Standards and samples (10 µL) were transferred 
onto a 96-well plate in duplicate followed by the incubation step as described in the 
manufacturer’s protocol (Mouse Insulin ELISA, Cat No. 10-1247-01—Mercodia, Diagenics, 
Milton Keynes, UK). The absorbance was measured at 450 nm using a microplate reader. 
2.9. SNAP-25 Protein Expression 
The expression of SNAP-25 protein was quantified by immunoblotting. Protein (10 µg) 
was loaded onto gels and following transfer, membranes were incubated with rabbit-anti­
rat SNAP-25 antibody (Cat No. ab5666—Abcam, Abcam, Cambridge, UK) (1 µg/mL). Goat 
anti-rabbit conjugated to horseradish peroxidase (Cat No. ab205718—Abcam, Abcam, Cam­
bridge, UK) at a dilution of 1:2000 was used as the secondary antibody. Blots were probed 
with goat polyclonal anti β-actin (Cat No. ab8229—Abcam, Abcam, Cambridge, UK) at 
1:500 dilution as a loading control. The membrane was visualised using electrochemilumi­
nescence Western blotting detection reagent, and analysed by scanning densitometry using 
Azure Biosystems 600 imaging system (Azure Biosystem, Dublin, CA, USA). Blots were 
quantified using imageJ (NIH, Bethesda, MD, USA). 
2.10. Cell Culture with Transferrin Treatments 
MIN6 cell ferritin protein content was determined using a commercial ELISA kit 
according to the manufacturer’s instructions following treatment of cells with human 
Cells 2021, 10, 1141 5 of 20 
transferrin (Sigma Aldrich, Poole, UK) at 0.005, 0.05, 0.5, 2, and 5 g/L for 24 h in media 
supplemented with tolbutamide. Iron and glucose were added as described previously in 
Section 2.4. 
2.11. Statistical Analysis 
The data are presented as the mean ± SEM and the differences between samples 
were analysed via one-way ANOVA followed by Tukey’s multiple comparisons post hoc 
test (PRISM software package, Version 8, GraphPad Software Inc., San Diego, CA, USA). 
Results were considered significantly different if p < 0.05. 
3. Results 
3.1. Assessment of Total Cellular Iron Content upon Exposure to Transferrin 
MIN6 cells were exposed to various concentrations (0.005, 0.05, 0.5, 2, and 5 g/L) 
of transferrin. Figure 1a shows that the highest total iron content was obtained from 
5 g/L (32.42 ± 0.78 ng/mg). This was followed by 0.005 g/L (28.36 ± 0.05 ng/mg protein) 
and 0.05 g/L (27.5 ± 0.9 ng/mg protein) as the second and the third highest total iron 
content, respectively. The 0.5 g/L sample exhibited the lowest total cellular iron content 
(24.10 ± 0.05 ng/mg protein). 
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Figure 1. Effect of transferrin treatments alone or in combination with iron on MIN6 cell intracellular iron content. Data 
are presented as follows: (a) Dose-response effects of a range of transferrin concentrations (0.005 g/L, 0.05 g/L, 0.5 g/L 
and 5 g/L) loaded into MIN6 cells for 24 h. The data represent mean ± SEM, n = 3. * p < 0.018. (0.005. g/L vs. 0.5 g/L), * p < 
0.033 (0.005 g/L vs. 5 g/L). (b) Effects of 0.05 g/L transferrin loaded into MIN6 cells in combination with 20 μM or 100 μM 
for 24 h. (c) Effects of 0.5 g/L transferrin loaded into MIN6 cells in combination with 20 μM or 100 μM for 24 h. (d)Effects 
of 2 g/L transferrin loaded into MIN6 cells in combination with 20 μM or 100 μM for 24 h. (e) Effects of 5 g/L transferrin 
loaded into MIN6 cells in combination with 20 μM or 100 μM for 24 h. The data (b–e) represent mean ± SEM, n = 3. Sig-
nificances are as follows; * p < 0.048 (0.05 g/L),* p < 0.0138 (0.5 g/L), ** p < 0.0036 (2 g/L), ** p < 0.0031 (5 g/L). 
Iron content levels were progressively decreased concomitant with decreasing trans-
ferrin concentrations. Transferrin concentration of 2 g/L showed the second highest total 
iron content (63.84 ± 12.52%) followed by 0.5 g/L (57.13 ± 16.70%) and 0.05 g/L (55.02 ± 
20.89%), respectively. The addition of increasing transferrin concentrations to MIN6 cells 
thus results in elevated total cellular iron content levels. Interestingly, identical effects 
were observed at 48 and 72 h upon quantifying total iron content levels in the absence of 
transferrin (Figure 2b), although total iron content increased significantly in the presence 
of transferrin, particularly at 100 μM iron (Figure 1e). The reason that total iron content 
increased in the presence of transferrin might be due to the presence of preexisting iron-
bound transferrin along with the treatment iron concentrations (20 μM or 100 μM). Thus, 
it is observed that the range of iron concentrations MIN6 cells were exposed to have no 
significant difference in cellular iron content compared to cells in the absence of transfer-
rin. 
3.2. Total Iron Content in the Absence of Transferrin 
MIN6 cells were incubated in the presence of 20 μM (control) and 100 μM high iron 
or physiological and supraphysiological glucose (5.5 mM and 11 mM, respectively), or 
combinations of iron and glucose, all with the addition of tolbutamide for 3, 24, 48, and 72 
h. As shown in Figure 2, iron or glucose or combinations thereof demonstrated no change 
on intracellular iron content compared to control (3 h). At 24 h, iron and glucose concen-
trations exhibited a trend towards higher iron content compared to control, however these 
effects were not statistically significant (p > 0.05). The highest iron content was exhibited 
upon treatment with 100 μM iron and 5.5 mM glucose and resulted in a 41 ± 17.1% increase 


























































































Figure 1. Effect of transferrin treatments alone or i  combination with iron on MIN6 cell intracellular 
iron content. Data are presented as follows: (a) Dose-response effects of a range of transferrin 
concentrations (0.005 g/L, 0.05 g/L, 0.5 g/L and 5 g/L) loaded into MIN6 cells for 24 h. The data 
represent mean ± SEM, n = 3. * p < 0.018. (0.005. g/L vs. 0.5 g/L), * p < 0.033 (0.005 g/L vs. 5 g/L). 
(b) Effects of 0.05 g/L transferrin loaded into MIN6 cells in combination with 20 µM or 100 µM o  
24 h. (c) Effects of 0.5 g/L transferrin loaded into MIN6 cells in combination with 20 µM or 100 µM 
for 24 h. (d)Effects of 2 g/L transferrin loaded into MIN6 cells in combination with 20 µM or 100 µM 
for 24 h. (e) Effects of 5 g/L transferrin loaded into MIN6 cells in combination with 20 µM or 100 µM 
for 24 h. The data (b–e) represent mean ± SEM, n = 3. Significances are as follows; * p < 0.048 
(0.05 g/L),* p < 0.0138 (0.5 g/L), ** p < 0.0036 (2 g/L), ** p < 0.0031 (5 g/L). 
Figure 1b–e demonstrates a range of concentrations of transferrin with the addition of 
two selected iron concentrations (20 µM; control and 100 µM; high iron) on total cellular 
iron content. The data show that addition of 20 µM iron did not result in increasing iron 
content at most transferrin concentrations. However, 100 µM iron demonstrated higher 
total iron conte t throughout all conditions. Figure 1e represents the highest transferrin 
concentration (5 g/L) with the addition of 100 µM iron and leads o a significant increase 
(70.92 ± 17.21%) in iron con en compar d to 20 µM iron (p < 0.05). 
Iron content levels were progressively decreased concomitant with decreasing trans­
ferrin concentrations. Transferrin concentration of 2 g/L showed the second highest to­
tal iron content (63.84 ± 12.52%) followed by 0.5 g/L (57.13 ± 16.70%) and 0.05 g/L 
(55.02 ± 20.89%), respectively. The addition of increasing transferrin concentrations to 
MIN6 cells thus results in elevated total cellular iron content levels. Interestingly, identical 
effects were observed at 48 and 72 h upon quantifying total iron content levels in the 
absence of transferrin (Figure 2b), although total iron content increased significantly in the 
presence of transferrin, particularly at 100 µM iron (Figure 1e). The reason that total iron 
content increased in the presence of transferrin might be due to the presence of preexisting 
iron-bound transferrin along with the treatment iron concentrations (20 µM or 100 µM). 
Thus, it is observed that the range of iron concentrations MIN6 cells were exposed to 
have no significant difference in cellular iron content compared to cells in the absence 
of transferrin. 
3.2. Total Iron Content in the Absence of Transferrin 
MIN6 cells were incubated in the presence of 20 µM (control) and 100 µM high iron 
or physiological and supraphysiological glucose (5.5 mM and 11 mM, respectively), or 
combinations of iron and glucose, all with the addition of tolbutamide for 3, 24, 48, and 72 h. 
As shown in Figure 2, iron or glucose or combinations thereof demonstrated no change on 
intracellular iron content compared to control (3 h). At 24 h, iron and glucose concentrations 
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exhibited a trend towards higher iron content compared to control, however these effects 
were not statistically significant (p > 0.05). The highest iron content was exhibited upon 
treatment with 100 µM iron and 5.5 mM glucose and resulted in a 41 ± 17.1% increase 
compared to control (24 h). 
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Figure 2. Effect varying of iron and glucose concentrations on intracellular iron content. To quantify the intracellular ac-
cumulation of iron, MIN6 cells were exposed to iron (20 μM and 100 μM) and/or glucose (5.5 mM and 11 mM) with the 
addition of tolbutamide as a secretagogue. Cells were incubated in a time course at 3 and 24 h (a), 48 and 72 h (b). End 
points measurements were determined using FerroZine™-based colorimetric assay. The data represent mean ± SEM, n = 
4. Significance compared to control are as follows ** p < 0.004 (11 mM Glu (C2)—48 h), * p < 0.017 (C3—48 h), *** p < 0.0004 
(C4—48 h); * p < 0.014 (5.5 mM Glu (C1)—72 h), *** p < 0.001 (C2—72 h), *** p < 0.0003 (C3—72 h), **** p < 0.0001 (C4—72 
h). 
Furthermore, iron content was significantly increased at 48 and 72 h at 100 μM iron 
and 11 mM glucose concentrations compared to control (p < 0.05). However, 5.5 mM glu-
cose did not demonstrate a significant effect (p > 0.05) compared to control. The 100 μM 
concentration exhibited a 34.44 ± 4.65% increase in iron content compared to control (48 h 
incubation). Similar to 48 h incubation, 100 μM iron and 11 mM glucose concentrations 
alone demonstrated significant changes, with 100 μM iron exhibiting a 2-fold increase 
compared to control (76.32 ± 2.66 nmol/mg protein vs. 34.80 ± 0.38 nmol/mg protein and 
55.13 nmol/mg protein ± 0.93 vs. 34.80 ± 0.38 nmol/mg protein, respectively) (72 h).  
These data suggest that excess iron in the presence of glucose may exert effects on 
MIN6 cell iron metabolism after 24 h.  
Figure 2. Ef ect f iron and glucose concentrations o  intrace lular iron content. To quantify the intracellular 
accumulation of iron, MIN6 cells were exposed to iron (20 µM and 100 µM) and/or glucose (5.5 mM and 11 mM) with the 
addition of tolbutamide as a secretagogue. Cells were incubated in a time course at 3 and 24 h (a), 48 and 72 h (b). End 
points measurements were determined using FerroZine™-based colorimetric assay. The data represent mean ± SEM, n = 4. 
Significance compared to control are as follows ** p < 0.004 (11 mM Glu (C2)—48 h), * p < 0.017 (C3—48 h), *** p < 0.0004 
(C4—48 h); * p < 0.014 (5.5 mM Glu (C1)—72 h), *** p < 0.001 (C2—72 h), *** p < 0.0003 (C3—72 h), **** p < 0.0001 (C4—72 h). 
Furthermore, iron content was significantly increased at 48 and 72 h at 100 µM iron 
and 11 mM glucose concentrations compared to control (p < 0.05). However, 5.5 mM 
glucose did not demonstrate a significant effect (p > 0.05) compared to control. The 100 µM 
concentration exhibited a 34.44 ± 4.65% increase in iron content compared to control (48 h 
incubation). Similar to 48 h incubation, 100 µM iron and 11 mM glucose concentrations 
alone demonstrated significant changes, with 100 µM iron exhibiting a 2-fold increase 
compared to control (76.32 ± 2.66 nmol/mg protein vs. 34.80 ± 0.38 nmol/mg protein and 
55.13 nmol/mg protein ± 0.93 vs. 34.80 ± 0.38 nmol/mg protein, respectively) (72 h). 
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These data suggest that excess iron in the presence of glucose may exert effects on 
MIN6 cell iron metabolism after 24 h. 
3.3. Cellular Ferritin Content 
As shown in Figure 3, iron and glucose demonstrated no effect on MIN6 cell ferritin 
content at 3 h incubation. In addition, conditions containing iron and glucose in combina­
tion also exhibited no change in ferritin content. Glucose treatment appeared to slightly 
increase ferritin content and iron slightly reduced it at 3 h. Similar effects remained observ­
able at 24 h at which iron, glucose, and combinations of iron and glucose demonstrated no 
short-term effects on iron storage. 
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Figure 3. The effect of iron (20 µM and 100 µM), glucose (5.5  and 11 mM), and combinations of iron and glucose, all 
with the addition of tolbutamide as a secretagogue on MIN6 cells on ferritin content. This assessment was performed at four 
different time points [3 and 24 h (a), and 48 and 72 h (b)]. The data represent mean ± SEM, n = 4. Significance compared 
to control is as follows * p < 0.028 (11 mM Glu (C2)—48 h), * p < 0.023 (20 µM Fe (C3)—48 h), ** p < 0.006 (100 µM Fe 
(C4)—48 h); * p < 0.025 (C4—72 h). 
All iron (20 µM and 100 µM) and glucose (5.5 and 11 mM) treatments led to significant 
increases in ferritin content at 48 h. High iron exhibited 15-fold higher ferritin content than 
its control (271 ± 30.40 ng/mg protein vs. 17.81 ± 7.80 ng/mg protein), which was followed 
by 20 µM iron with a 5-fold increase (173.02 ± 29.91 ng/mg protein vs. 17.81 ± 7.81 ng/mg 
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protein). Moreover, 11 mM glucose demonstrated ferritin content almost twice as high as 
control (47.72 ± 3.50 %). In contrast, 5.5 mM glucose showed no effect on ferritin content 
compared to control at 72 h incubation. At high iron, ferritin content was significantly 
increased at levels four times higher (76.13 ± 11.15%) than its control (p < 0.05). Thus, 
MIN6 cells exposed to high iron concentration (100 µM) result in high ferritin content at 
both 48 h and 72 h. 
3.4. Estimation of Lipid Peroxidation 
Quantification of cellular lipid peroxidation is crucial to providing information on 
the effects of ROS-mediated oxidative stress. As shown in Figure 4, iron (20 µM and 100 
µM) and glucose (5.5 mM and 11 mM) demonstrated no effects on MDA levels both at 3 
and 24 h incubation. Although slight changes were observed at glucose concentrations 
(5.5 mM and 11 mM) alone and conditions containing iron and glucose combinations, MDA 
levels were increased not significantly compared to control (p > 0.05) (24 h). In contrast, 
MDA levels were significantly increased at high iron (100 µM) and glucose concentrations 
(5.5 mM and 11 mM) at both 48 and 72 h incubation (p < 0.05). 
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Figure 4. Determination of lipid peroxidation marker (MDA) performed by TBARS assay (a) following 3 h and 24 h incubation 
with test conditions; iron (20 µM and 100 µM) and/or glucose (5.5 mM and 11 mM), and combinations of iron and glucose and 
(b) following 48 h and 72 h incubation with these test conditions (b). High iron and glucose (100 µM and 11 mM respectively) in 
presence of tolbutamide as a secretagogue increased the concentration of MDA compared to control both at 48 and 72 h time 
points. The data represent mean ± SEM; n = 4. ** p < 0.0012 (5.5 mM glu—48 h), ** p < 0.001 (11 mM glu—48 h), *** p < 0.0002 
(100 µM Fe—48 h), *** p < 0.0003 (5.5 mM glu—72 h), **** p < 0.0001 (11 mM glu and 100 µM Fe—72 h). 
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High iron and high glucose concentrations exhibited more than 50% higher MDA 
levels compared to its control with high iron demonstrating the highest MDA level, 62.73% 
higher than its control (3323.87 ± 0.82 nmol/mg protein vs. 120.82 ± 2.47 nmol/mg 
protein). The effect remained at 72 h incubation at which high iron and high glucose 
exhibited significantly increased levels of MDA compared to control (p < 0.05). Consistent 
with the result at 48 h, high iron resulted in the highest MDA level with a 51% increase 
compared to control (129 ± 0.81 nmol/mg protein vs. 63.7 ± 0.52 nmol/mg protein). 
3.5. Assessment of Cellular Viability 
The results shown in Figure 5 demonstrate the effects of various concentrations of 
iron, glucose, and combinations of iron and glucose with the addition of tolbutamide on 
MIN6 cell viability at 3, 24, 48, and 72 h. Exposure to both 5.5 mM and 11 mM glucose 
concentrations exhibited significantly increased cell viability, 21.63% and 19.21% higher 
than the control, respectively (3 h incubation). Although iron concentrations demonstrated 
a decreased percentage of cell viability, the levels were not significant (p > 0.05). At 24 h 
incubation, similar effects were observed with both iron and glucose concentrations; glu­
cose concentrations increased cell viability, but iron concentrations resulted in a decrease. 
However, glucose concentrations exerted a non-significant effect compared to control, 
whereas both 20 µM and high 100 µM iron demonstrated significant reductions (47.15% 
and 46.27%, respectively). 
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Figure 5. The effect of iron and glucose on MIN6 cell viability. Cytotoxicity assessment was performed by PrestoBlue®
assay at four incubation times [(3 and 24 h (a), 48 and 72 h (b)]. MIN6 cells were exposed to various concentrations of iron
(20 μM and 100 μM) and/or glucose (5.5 mM and 11 mM), and combinations of iron and glucose with the addition of
tolbutamide as a secretagogue. The data represent mean ± SEM, n = 4. * p < 0.02 represents significance compared to control. 
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Figure 5. The effect of iron and glucose on MIN6 cell viability. Cytotoxicity assessment was performed by PrestoBlue®
assay at four incubation times [(3 and 24 h (a), 48 and 72 h (b)]. MIN6 cells were exposed to various concentrations of iron
(20 μM and 100 μM) and/or glucose (5.5 mM and 11 mM), and combinations of iron and glucose with the addition of
tolbutamide as a secretagogue. The data represent mean ± SEM, n = 4. * p < 0.02 represents significance compared to control. 
Figure 5. The effect of iron and glucose on MIN6 cell viability. Cytotoxicity assessment was performed by PrestoBlue® assay 
at four incubation times [(3 and 24 h (a), 48 and 72 h (b)]. MIN6 cells were exposed to various concentrations of iron (20 µM 
and 100 µM) and/or glucose (5.5 mM and 11 mM), and combinations of iron and glucose with the addition of tolbutamide 
as a secretagogue. The data represent mean ± SEM, n = 4. * p < 0.02 represents significance compared to control. 
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At 48 h incubation, glucose concentrations demonstrated slight changes, in which 
5.5 mM glucose demonstrated a non-significant increase in cell viability (p > 0.05), but high 
11 mM glucose resulted in the opposite effect. In contrast, high iron (100 µM) concentration 
significantly reduced the percentage of cell viability, with a 35% reduction compared to 
control. Similar effects were also observed at 72 h at which high iron exhibited a 46% 
reduction of cell viability, followed by high glucose with 40.54% reduction in cell viability. 
These results are generally consistent with data obtained in previous analyses, suggesting 
high iron and high glucose may lead to impairments of cellular function. 
3.6. Assessment of Insulin Content 
Insulin content was quantified to determine the balance between insulin synthesis and 
secretion. As shown in Figure 6, iron and glucose slightly altered the level of intracellular 
insulin content in which the values were increased, although non-significantly compared 
to control following a 1 h incubation (p > 0.05). In addition, the combinations of iron and 
glucose concentrations demonstrated no change in insulin content. In contrast, following 
12 h incubation, 100 µM iron (53.01 µg/mg protein vs. 38.13 µg/mg protein) exhibited a 
significant increase in insulin content compared to control (Figure 6). Glucose treatment 
(11 mM) demonstrated higher insulin content but was not statistically significant (p > 0.05). 
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Figure 6. The effect of iron and glucose on intracellular insulin content. Measurements were 
performed using insulin ELISA in cultured cells. MIN6 cells were exposed to various concentrations 
of iron, glucose, and combinations of iron and glucose with t e addition f t lbutamide at designated 
i cubation times. Th  data repres nt mean ± SEM, n = 3. * p < 0.0193  ( 3) 12 h), 
* p  0.022 (100 µM Fe (C4)—12 h), * p < .0148 (11 mM Glu + 100 µM Fe (C8)—12 h); * p < 0.0229 
(5.5 mM Glu + 100 uM Fe (C6)—24 h), * p < 0.011 (11 mM Glu + 100 µM Fe (C8)—24 h). 
At 24 h incubation, both 20 µM and 100 µM iron led to a reduction in insulin content 
that was not statistically significant (20 µM Fe: 12.27%; 100 µM Fe: 10.22%), whereas 5.5 mM 
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glucose led to a slight increase that was not statistically significant (5.5 mM Glu: 4%). Iron 
and glucose had no influence on insulin content at 1 h but began to exert significant effects 
at 12 h following treatment incubation. At 24 h, iron and glucose demonstrated contrasting 
effects; iron treatment showed a trend towards reduced insulin content whereas glucose 
treatments increased it. 
3.7. Assessment of Insulin Secretion 
The data in Figure 7 showed insulin secretion levels upon exposure to various condi­
tions of iron, glucose, and combinations of iron and glucose at 5, 10, 30, and 60 min. 
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Figure 7. The effect of treatment with varying concentrations of iron, glucose, and combinations of iron and glucose with the 
addition of tolbutamide on MIN6 cells insulin secretion. (a) The effect of treatment with 5.5 mM and 11 mM of glucose with the 
addition of tolbutamide on MIN6 cells insulin secretion following 3 h and 24 h incubation. The data represent mean ± SEM, n = 
3. (b) The effect of treatment with 20 µM and 100 µM iron with the addition of tolbutamide on MIN6 cells insulin secretion 
following 3 h and 24 h incubation. The data represent mean ± SEM, n = 3. (c) The effect of treatment with 5.5 mM and 11 mM of 
glucose and/or 20 µM and 100 µM iron and combinations of iron and glucose with the addition of tolbutamide on MIN6 cells 
insulin secretion following 3 h and 24 h incubation. The data represent mean ± SEM, n = 3. (d) The effect of treatment incubation 
with varying concentrations of iron, glucose, and combinations of iron and glucose with the addition of tolbutamide on MIN6 
cells insulin secretion acutely (5, 10, 30, 60 min). The data represent mean ± SEM, n = 3. * p < 0.0036 (5.5 mM Glu (C1)—10 min), 
** p < 0.037 (11 mM Glu (C2)—10 min), ** p < 0.005 (20 µM Fe (C3)—10 min), * p < 0.026 (5.5 mM Glu + 20 µM Fe (C6)—10 min), 
* p < 0.01 (11 mM Glu + 100 µM Fe (C8)—10 min); * p < 0.05 (C1—30 min), * p < 0.033 (C2—30 min), * p < 0.016 (C3—30 min), * p 
< 0.026 (C6—30 min), * p < 0.01 (C8—30 min); * p < 0.013 (C3—60 min). (e) The effect of treatment with varying concentrations 
of iron, glucose, and combinations of iron and glucose with the addition of tolbutamide on MIN6 cells insulin secretion follow-
ing 24 h (5, 10, 30, 60 min). The data represent mean ± SEM, n = 3. * p < 0.049 [11 mM Glu (C2)—24 h (5 min)], * p < 0.022 [20 µM 
Fe (C3)—24 h(5 min], ** p < 0.004 [100 µM Fe (C4)—24 h(5 min], * p < 0.013 [5.5 mM Glu + 100 µM Fe—24 h (C6)(5 min)], ** p < 
0.003 [11 mM Glu + 100 µM Fe—24 h (C8)(5 min)]; * p < 0.034 [C2—24 h(10 min)], * p < 0.022 [C3—24 h(10 min)], * p < 0.02 (C4—
24 h(10 min)], ** p < 0.005 [C6—24 h(10 min)], * p < 0.027 [C8—24 h(10 min)]; * p < 0.015 [C2—24 h(30 min)], ** p < 0.004 [C3—24 
Figure 7. The effect of treatment with varying concentrations of iron, glucose, and combinations of iron and glucose 
with the addition of tolbutamide on MIN6 cells insulin secretion. (a) The effect of treatment with 5.5 mM and 11 mM of 
glucose with the addi ion of tolbutamide on MIN6 cells insulin s retion following 3 h and 24 h incubation. The data
represent mean ± SEM, n = 3. (b) The effect of treatment with 20 µM and 100 µM iron with the addition of tolbutamide on 
MIN6 cells insulin secretion following 3 h and 24 h incubation. The data represent mean ± SEM, n = 3. (c) The effect of 
treatment with 5.5 mM and 11 mM of glucose and/or 20 µM and 100 µM iron and combinations of iron and glucose with the 
addition of tolbutamide on MIN6 cells insuli  secretion following 3 h and 24 h incubation. The data represent mea  ± SEM, 
n = 3. (d) The effect of treatment incubation with varying concentrations of iron, glucose, and combinations of iron and 
glucose with the addition of tolbutamide on MIN6 cells insulin secretion acutely (5, 10, 30, 60 min). The data represent 
mean ± SEM, n = 3. * p < 0.0036 (5.5 mM Glu (C1)—10 min), ** p < 0.037 (11 mM Glu (C2)—10 min), ** p < 0.005 (20 µM 
Fe (C3)—10 min), * p < 0.026 (5.5 mM Glu + 20 µM Fe (C6)—10 min), * p < 0.01 (11 mM Glu + 100 µM Fe (C8)—10 mi ); 
* p < 0.05 (C1—30 min), * p < 0.033 (C2—30 min), * p < 0.016 (C3—30 min), * p < 0.026 (C6—30 min), * p < 0.01 (C8—30 min); 
* p < 0.013 (C3—60 min). (e) The effect of treatment with varying concentrations of iron, glucose, and combinations of 
iron and glucose with the addition of tolbutamide on MIN6 cells insulin secretion following 24 h (5, 10, 30, 60 min). The 
data represent mean ± SEM, n = 3. * p < 0.049 [11 mM Glu (C2)—24 h (5 min)], * p < 0.022 [20 µM Fe (C3)—24 h (5 min)], 
** p < 0.004 [100 µM Fe (C4)—24 h (5 min)], * p < 0.013 [5.5 mM Glu + 100 µM Fe—24 h (C6)(5 min)], ** p < 0.003 [11 mM 
Glu + 100 µM Fe—24 h (C8)(5 min)]; * p < 0.034 [C2—24 h (10 min)], * p < 0.022 [C3—24 h (10 min)], * p < 0.02 (C4—24 h 
(10 min)], ** p < 0.005 [C6—24 h (10 min)], * p < 0.027 [C8—24 h (10 min)]; * p < 0.015 [C2—24 h (30 min)], ** p < 0.004 
[C3—24 h (30 min)], * p < 0.016 [C4—24 h (30 min)], ** p < 0.005 [C6—24 h (30 min)], * p < 0.018 [C8—24 h (30 min)]; 
* p < 0.044 [C2—24 h (60 min)], * p < 0.034 (C3, C4, C6—24 h (60 min)]. 
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The results show insulin secretion levels following treatment with glucose compared 
to control (Figure 7a), iron against control (Figure 7b), combinations of iron and glucose 
against control (Figure 7c), and measurements of iron, glucose, and combinations of iron 
and glucose at 5, 10, 30, and 60 min (acute) (Figure 7d), which was also applied at 24 h 
incubation (long term) (Figure 7e). 
As shown in Figure 7a–c, both 5.5 mM and 11 mM glucose concentrations (5.5 mM: 
10.50 µg/mg protein vs. 9.02 µg/mg protein; 11 mM: 9.73 µg/mg protein vs. 9.02 µg/mg 
protein) slightly increased insulin secretion both at 3 and 24 h (Figure 7a). The 20 µM 
concentration of iron had no effect on insulin secretion (8.73 µg/mg protein vs. 8.71 µg/mg 
protein), while 100 µM iron showed a trend towards increased insulin secretion (9.26 µg/mg 
protein vs. 8.71 µg/mg protein) compared to control (3 h) (Figure 7b). This was also 
observed at 24 h incubation. Furthermore, insulin secretion was slightly increased in all 
conditions containing iron and glucose combinations compared to control. However, the 
treatment containing 20 µM iron and 5.5 mM glucose combinations exhibited the highest 
insulin secretion at both 3 and 24 h incubation (10.2 µg/mg protein vs. 8.27 µg/mg protein, 
33 µg/mg protein vs. 17.70 µg/mg protein, respectively) (Figure 7c). 
Short-term incubations were conducted on MIN6 cells where changes occurred under 
all conditions at several incubations. At 5 min incubation, 100 µM iron and 11 mM glucose 
exhibited higher insulin secretion with 33% and 26.2% compared to control, respectively. 
In addition, the combinations of iron and glucose demonstrated a trend towards 
reduced insulin secretion compared to control (p > 0.05). However, 20 µM iron reduced 
insulin secretion by 33.31%, whereas 100 µM iron resulted in no change compared to 
control (10 min incubation). Insulin secretion (5.5 mM: 9.59% and 11 mM: 14%) showed a 
trend towards significance following treatment with both glucose concentrations (p > 0.05). 
At 30 min incubation, 100 µM iron and 11 mM glucose increased insulin secretion non-
significantly (p > 0.05). At 30 min incubation, 100 µM iron and 11 mM glucose increased 
insulin secretion non-significantly (p > 0.05). In contrast, 20 µM iron reduced insulin 
secretion by 13.34%, but secretion was increased (18.82%) at 100 µM iron and with 11 mM 
glucose which had the highest insulin secretion (23.11% compared to control) (60 min 
incubation) (Figure 7d). 
Acute changes at 5, 10, 30, and 60 min were investigated and insulin secretion was 
measured (Figure 7e). Here, 100 µM iron alone and 11 mM glucose alone demonstrated sig­
nificant reductions in levels of insulin secretion (63.53%, 56.08%, 74.53, 47.21% and 31.71%, 
35.13%, 34.50%, 43.42%, respectively) across various time courses compared to control 
(p > 0.05). This was also shown by conditions containing iron and glucose combinations. 
3.8. Expression of SNAP-25–Mediated Insulin Exocytosis 
MIN6 cells were exposed to pre-determined concentrations of iron (20 µM and 100 µM) 
and glucose (5.5 mM and 11 mM) for 24 and 48 h. Figure 8a–c depicts the measurements 
of SNAP-25 protein expression using immunoblotting. The high iron and glucose concen­
tration decreased the SNAP-25 expression levels at both time points, compared to that in 
the control. The high iron concentration produced the lowest expression of this particular 
protein in comparison to that under all the other conditions at both 24 and 48 h. 
A significant reduction in MIN6 β-cell SNAP-25 protein expression was evident at 
24 h upon exposure to 100 µM iron (65 ± 13.09 vs. 293 ± 0.42) and 11 mM glucose 
(34.71 ± 11.30 vs. 293 ± 0.42). A similar expression of SNAP-25 was also observed after 
48 h of incubation, at which high iron and high glucose concentrations induced significant 
reductions compared to that in the control (48.40 ± 6.52 vs. 132.45 ± 14.33 and 43.13 ± 9.52 
vs. 132.45 ± 14.3, respectively). Moreover, 20 µM iron concentration did not significantly 
decrease SNAP-25 expression levels compared to that in the control (62.62 ± 4.70 vs. 
132.45 ± 14.33) after 48 h of incubation. However, after 24 h of incubation, it decreased the 
SNAP-25 levels significantly compared to that in the control (86.61 ± 2.71 vs. 293 ± 0.42). 
These results suggest that 100 µM iron and 11 mM glucose concentrations significantly 
reduce the levels of SNAP-25 in MIN6 cells even after 24 h. 
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ence of iron (20 µM and 100 µM) and glucose (5.5 mM and 11 mM) with the addition of tolbutamide as a secretagogue. 
Protein expression was identified using Western blotting. (a) Distinctive bands of SNAP-25 (24 and 48 h) and β-actin (24 
and 48 h). Gel loading was as follows (from top left): lane 1—ctrl, lane 2—normal glucose (5.5 mM) (C1), lane 3—high 
glucose (11 mM) (C2), lane 4—normal iron (20 µM) (C3), lane 5—high iron (100 µM) (C4); (from middle right): lane 1—
ctrl, lane 2—C1, lane 3—C2, lane 4—C3, lane 5—C4. (b) Expression of SNAP-25 at 24 h normalised against β-actin. (c) 
Expression of SNAP-25 at 48 h normalised against β-actin. The data represent mean ± SEM; n = 4. **** p < 0.0001 (24 h), ** 
p < 0.0061 (48 h), *** p < 0.0005, **** p < 0.0001 (48 h). 
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Figure 8. SNAP-25 protein expressions in pancreatic - l  ( ence 
of iron (20 µM and 100 µM) and glucose (5.5 mM and 11 mM) with the addition of tolbutamide as a secretagogue. Protein 
expression was identified using Western blotting. (a) Distinctive bands of SNAP-25 (24 and 48 h) and β-actin (24 and 
48 h). Gel loading was as follows (from top left): lane 1—ctrl, lane 2—normal glucose (5.5 mM) (C1), lane 3—high glucose 
(11 mM) (C2), lane 4—normal iron (20 µM) (C3), lane 5—high iron (100 µM) (C4); (from middle right): lane 1—ctrl, lane 
2—C1, lane 3—C2, lane 4—C3, lane 5—C4. (b) Expressio  of SNAP-25 at 24 h normalised against β-actin. (c) Expression of 
SNAP-25 at 48 h normalised against β-actin. The data represent mean ± SEM; n = 4. **** p < 0.0001 (24 h), ** p < 0.0061 
(48 h), *** p < 0.0005, **** p < 0.0001 (48 h). 
4. Discussi n 
Diabetes mellitus is a complex disease with multiple complications affecting people of 
different ages and sex [21]. Iron is an important nutrient that has been identified as one 
of the factors contributing to the progression of T2DM, although the mechanisms are not 
well clarified. Iron participates in many biological processes in the human body, including 
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playing an essential role in the production of ATP and metabolic processes such as DNA 
repair and replication, and regulation of gene expression [22]. Higher levels of intracellular 
iron can be involved in the regulation of cell proliferation by regulating transcription 
factors, controlling cell cycle progression and apoptosis [23]. 
4.1. Exposure of MIN6 β-Cells to High Iron Levels Results in Significantly Elevated Cellular Iron 
Accumulation 
Iron metabolism, which involves its uptake, distribution, storage, and secretion, has 
been well established. Ferric iron is normally bound to apotransferrin forming diferric-Tf, 
with the purpose of distributing iron throughout the body. The experiments summarised 
in Figure 1 demonstrated that although the addition of transferrin bound to iron resulted 
in significant levels of total iron content intracellularly (p < 0.05), the same effects remained 
in its absence (Figure 2), demonstrating that high iron (100 µM) led to overall higher 
total iron content compared to all other cell treatments. Once iron enters into cells, it can 
be transported into mitochondria or stored within the cytoplasm as ferritin. Ferritin is 
considered a major store of intracellular iron, with storage being a key component of iron 
metabolism. This protein is fundamental in controlling the amount of iron available to 
the body. It has the ability to store and release iron in a controlled fashion, which helps to 
prevent iron disorders like iron overload, anaemia, and other iron-related diseases. Serum 
ferritin is a crucial measurement as this protein is commonly used as an indicator of tissue 
iron status. The results illustrated in Figure 3 show ferritin content increased in an iron 
concentration-dependent manner, when incubated at 48 h (fifteen times higher) and 72 h 
(four times higher) with excess iron. These data correspond to total iron content (Figure 2) 
performed by colorimetric FerroZine™ assay, where similar results were obtained. 
Ford and Cogswell elucidated that an increase in ferritin has been positively correlated 
with the risk of developing T2DM [24]. This study is also supported by Aregbesola and 
colleagues, who suggested that ferritin levels above normal were related to an increased 
risk of diabetes mellitus [25]. The potential reason for increased ferritin in the β-cells may 
be due to the fact that ferritin exhibits antioxidant properties as it acts as a protective 
molecule against iron toxicity by sequestering excess free iron [26]. This is particularly 
relevant as β-cells are more sensitive to reactive oxygen radicals due to lack of substantial 
intracellular antioxidant enzyme defenses. Iron can be released from ferritin, converting 
Fe3+ into the more reactive Fe2+ form by the action of a reducing agent, and the release of 
reactive free iron may occur at a faster rate than what can be countered by the endogenous 
antioxidants [27]. Under this condition, elevated levels of free iron are released from ferritin. 
Interestingly, this phenomenon has also been observed in pre-diabetes, concomitant with 
low transferrin saturation levels [28]. The link between increased serum ferritin levels and 
the risk of diabetes mellitus remains to be fully understood. However, oxidative stress 
initiated by the release of excess free iron that acts as a catalyst for ROS generation may be 
a putative mechanism. 
4.2. Excess Iron in MIN6 β-Cells Results in ROS Generation, Lipid Peroxidation and Cytotoxic Effects 
In the present study, excess iron-generated ROS was shown to increase MDA (mea­
sured by TBARS) contributing to apoptosis initiation. Figure 4 showed that excess iron 
demonstrated higher MDA levels, which started at 48 h incubation likely as a result of ROS-
mediated cellular lipid peroxidative effects. Moreover, another major aldehyde product of 
this structure is 4-hydroxy-2-nonenal (HNE), characterised as a major toxic product and 
considered as weakly mutagenic [29]. It can be seen that there is a profound increase in 
MDA levels in the presence of excess iron, which suggests that there is increased production 
of free radicals [30]. These free radicals promote lipid peroxidation, resulting in the chain 
reaction that ultimately leads to damaging various molecules, eventually leading to cellular 
dysfunction [30]. 
As mentioned previously, iron has a dual role—it is essential in both cellular metabolism 
and aerobic respiration. However, the involvement of this metal leads to the formation 
of free radicals that can cause cellular toxicity and oxidative damage on the cellular com­
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ponents. The effect of excess iron and glucose on the viability of the cells was assessed 
(Figure 5). In line with the previous results, toxicity caused by excess iron exhibited a 
significant reduction in cell viability compared to control cells, both at 48 and 72 h (p < 0.05). 
This toxicity results from the production of ROS, causing β-cell dysfunction via decreased 
insulin gene expression [31]. If β-cells were exposed to these concentrations for a prolonged 
and repeated period, they may undergo exhaustion, promoting the inhibition of insulin 
secretion, and leading to irreversible damage. Furthermore, due to tight regulation of 
iron in mitochondria, it is susceptible to the generation of reactive free radicals even in 
conditions of minor elevations in iron levels. ROS mediates apoptosis of pancreatic islets, 
decreasing their capacity to secrete optimal levels of insulin [32]. 
4.3. Excess Iron in MIN6 β-Cells Results in Dysfunctions in Insulin Secretory Machinery 
Iron is known to be involved in the insulin secretory mechanism. Elevated iron levels 
can generate free radicals and formation of ROS. Figure 7 shows that excess iron pro­
gressively decreased secretion of insulin after a 24 h incubation. This could be caused 
by impairment of insulin secretion because of an elevated and continuous exposure of 
intracellular ROS [33]. Similar effects are also observed in measurements of insulin content 
(Figure 6). Impairment of insulin secretion and insulin resistance can lead to hypergly­
caemia, which is a known feature of T2DM. A study performed by Shaaban and colleagues 
(2016) concluded that excess iron negatively impacted insulin action in healthy people [34]. 
Furthermore, a considerable body of evidence indicates that excess iron increases the risk 
for insulin resistance in diabetes mellitus, as well as other diseases such as cardiovascular 
diseases both in nondiabetic and diabetic individuals [34]. 
The ultimate effect of chronic impairment of insulin secretion due to excess iron and 
glucose is oxidative stress in the mitochondria, and finally apoptosis [35]. When β-cells 
sense the presence of glucose, the cytosolic levels of Ca2+ increase owing to molecular 
processes. This increase stimulates and activates the SNARE machinery, which mediates 
insulin granule fusion with the plasma membrane [36]. It has been observed that SNARE 
core complexes, key proteins involved in insulin exocytosis, are likely to be sensitive 
towards oxidative stress [37]. It has also been shown previously that hydrogen peroxide as 
an endogenously generated ROS inhibits insulin secretion in isolated pancreatic islets [38]. 
SNAP-25 has been shown to be most sensitive to modification by ROS, possibly due to 
its distinctive structure, which is unable to anchor into the membrane due to the absence 
of a transmembrane segment [39]. Figure 8 shows that SNAP-25 expression diminishes 
in MIN6 cells in the presence of high iron and glucose concentrations for 24 and 48 h, 
compared to that in the control. A significant shift is apparent even at 24 h. These data are 
in accordance with earlier data collected in this study, which indicate that high iron and 
glucose concentrations significantly decrease insulin secretion (24 h) (p < 0.05) (Figure 7e). 
The alteration of this protein may cause insulin secretion perturbations associated with the 
regulation of Ca2+ dynamics and membrane potential in the β-cells [40]. Studies by others 
have shown that enhancing the level of exocytotic proteins can improve the longevity of 
cells and reduce the occurrence of diseases such as diabetes mellitus and neurodegenerative 
disorders [41]. 
4.4. Conclusions 
In summary, these data demonstrate that pancreatic β-cells are susceptible to excessive 
iron accumulation, which results in a reduction in cell viability and diminishing MIN6 
β-cell insulin secretion by causing reduced expression of key exocytotic proteins. Thus, 
this work further supports the notion of a mechanistic role for β-cell iron overload in the 
development and progression of T2DM. Further experiments are required to investigate 
this mechanism and the role of the mitochondria under iron-induced oxidative stress. 
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10 
.3390/cells10051141/s1, Figure S1: Growth pattern of MIN6 cells into mature pseudoislets. 
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